Recombinant Human Thrombopoietin receptor(MPL),partial

In Stock
Code CSB-EP014755HU
Size US$1726Purchase it in Cusabio online store
(only available for customers from the US)
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names MPL
Uniprot No. P40238
Research Area Immunology
Alternative Names C MPL; CD110; mpl; MPLV; Myeloproliferative leukemia protein; Myeloproliferative leukemia virus oncogene; Proto-oncogene c-Mpl; THCYT2; Thrombopoietin receptor; TPO R; TPO-R; TPOR; TPOR_HUMAN
Species Homo sapiens (Human)
Source E.coli
Expression Region 26-491aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 56.5kDa
Protein Length Extracellular Domain
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses.
Gene References into Functions
  1. JAK2V617F mutation was found in 37 (61.7%) patients with ET. Among 23 patients without JAK2V617F mutation, 7 (11.7%) had CALR mutation and 1 (1.7%) had MPL mutation. Fifteen (25.0%) patients were negative for all 3 mutations: JAK2V617F(-), CALR(-), and MPL(-). PMID: 29390868
  2. MPL and CALR genotypes show a similar clinical picture at essential thrombocythaemia diagnosis. Bone marrow histology in MPL-mutated ET is characterized by prominent megakaryocytic proliferation. PMID: 29934356
  3. These results indicate that lusutrombopag acts on human TPOR to upregulate differentiation and proliferation of megakaryocytic cells, leading to platelet production. PMID: 29274361
  4. The expression of TPO and c-Mpl was significantly decreased in the cITP group compared to the nITP group, suggesting that TPO and its receptor may play important roles in childhood cITP pathogenesis. PMID: 29313460
  5. A novel germ-line mutation of c-mpl gene in a sporadic case of essential thrombocythemia. PMID: 28391042
  6. This study demonstrated that absence of MPL mutation in stroke. PMID: 28625126
  7. MPL mutations and splenomegaly are risk factors for essential thrombocythemia progression into primary nyelofibrosis. PMID: 27768091
  8. goals were: (i) to identify other MPL mutations that should be tested in MPN patients by mutation-specific PCR; and (ii) to determine the amino acid requirements at position 515 to prevent TpoR self-activation PMID: 26437785
  9. Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis. PMID: 27519934
  10. MPL is up regulated in JAK2(V617F) ECs and contributes to the maintenance/expansion of the JAK2(V617F) clone over JAK2(WT) clone in vitro PMID: 27865175
  11. In tumor cell cultures, exogenous expression of MPL led to constitutive activation of STAT3 and 5, ERK1/2, and AKT, cytokine-independent growth, and reduction of apoptosis similar to the effects seen in the spontaneously outgrown cells. PMID: 27177927
  12. Essential Thrombocythemia and Primary Myelofibrosis patients with MPL mutations are at high risk for Thrombotic Events. PMID: 28766534
  13. Results show that mutant CALR induces autocrine, but not paracrine activation of MPL in myeloproliferative neoplasm. [review] PMID: 28741795
  14. these results demonstrate that MPL P106L is a receptor with an incomplete defect in trafficking. PMID: 28034873
  15. A newborn girl with congenitcal amegakaryocytic thrombocytopenia had a homozygous missense Trp154-to- Arg mutation in exon 4 of c-MPL. The same heterozygote mutation was detected in her mother, father, and 2 siblings. PMID: 26316487
  16. Normal FLT3 and negative expression of CD34 and cMPL may predict a longer overall survival in aute myeloid leukemia. PMID: 27993871
  17. we show that the positive charge of the CALR mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR and the thrombopoietin receptor MPL. PMID: 26951227
  18. In essential thrombocythemia, MPL mutations might be associated with a higher risk of fibrotic transformation and the presence of JAK2/MPL mutations with higher risk of thrombosis. PMID: 26890983
  19. PARP-1 has an important role in the progression of acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene PMID: 26314963
  20. mutant CALR promotes myeloproliferative neoplasm development by activating c-MPL and its downstream pathway. PMID: 26817954
  21. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. PMID: 26668133
  22. we describe a Mpl W515K somatic mutation in a paediatric case of ET who presented with Budd-Chiari syndrome. No paediatric patient harbouring a Mpl W515K mutation has been previously reported. PMID: 25970554
  23. His(499) regulates the activation of human TpoR and provides additional protection against activating mutations, such as oncogenic Asn mutations in the TM domain PMID: 26627830
  24. this study has shown that in a fraction of the so-called triple-negative ETs a significant proportion of patients have mutations in signaling molecules, more particularly in MPL. PMID: 26450985
  25. erythrocyte lineage enforces exclusivity through upregulation of EKLF and its lineage-specific cytokine receptor (EpoR) while inhibiting both FLI-1 and the receptor TpoR (also known as MPL) for the opposing megakaryocyte lineage PMID: 26159733
  26. Compared to normal controls, the frequency of the JAK246/1 haplotype was significantly higher among patients with JAK2V617F, JAK2Ex12del, or MPL mutations, whereas no significant difference was found among CALR mutation-positive patients PMID: 26614694
  27. Flow cytometric detection of MPL (CD110) as a diagnostic tool for differentiation of congenital thrombocytopenias. PMID: 25911549
  28. Using C-mannosylation defective mutant of c-Mpl, the C-mannosylated tryptophan residues at four sites (Trp(269), Trp(272), Trp(474), and Trp(477)) are essential for c-Mpl-mediated JAK-STAT signaling. PMID: 26505790
  29. MPL gene mutations are associated with essential thrombocythaemia and major thrombotic complications. PMID: 25573593
  30. Letter/Meta-analysis: thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases. PMID: 25761530
  31. MPL mutation is associated with myeloproliferative neoplasms. PMID: 25398833
  32. The effects of inhibition of the TPO/c-MPL pathway on enhancing the chemotherapy sensitivity of AML cells. PMID: 24085601
  33. The data supports the proposal of including MPL exon 10 mutations as major diagnostic markers for myeloproliferative neoplasms. PMID: 26071474
  34. CALR mutation, MPL mutation and triple negativity may have roles in lowering vascular risk in primary myelofibrosis PMID: 25482134
  35. Both immature and mature Mpl reach the cell surface. PMID: 24931576
  36. The P106L mutation functionally separates The activity of c-Mpl in downstream signaling from that in maintaining platelet homeostasis. PMID: 25538044
  37. Amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth switch (CGS) extending receptor stability improve the expansion capacity of human cord blood CD34(+) cells in the absence of exogenous cytokines. PMID: 25343958
  38. OTT1 regulates the alternative splicing of Mpl-TR, a truncated isoform of c-Mpl, which modulates Thrombopoietin-mediated signaling. PMID: 25468569
  39. Studies demonstrate that progression to AML is part of the natural history of MPL W515L-associated disease. PMID: 20823136
  40. Impaired transcriptional regulation of the MPL signaling that normally governs megakaryopoiesis and erythropoiesis underlies congenital amegakaryocytic thrombocytopenia. PMID: 23908116
  41. These experiments define a novel VEGF-miR-1-Mpl-P-selectin effector pathway in lung Th2 inflammation and herald the utility of miR-1 and Mpl as potential therapeutic targets for asthma. PMID: 24043765
  42. In migrating cancer stem cells isolated from primary human colorectal cancers, CD110(+) and CDCP1(+) subpopulations mediate organ-specific lung and liver metastasis. PMID: 23747337
  43. MPL W515L mutation in pediatric essential thrombocythemia. PMID: 23441089
  44. Different mutations of the human c-mpl gene indicate distinct hematopoietic diseases. PMID: 23351976
  45. Loss of heterozygosity of chromosome 1p involving the MPL location may represent a molecular mechanism of fibrotic transformation in MPL-mutated myeloproliferative neoplasms. PMID: 23575445
  46. MPL Baltimore mutation is associated with thrombocytosis. PMID: 23511495
  47. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. PMID: 23359689
  48. Up-regulation of wild-type MPL levels promotes leukemia development and maintenance through activation of the PI3K/AKT axis. PMID: 22613795
  49. High MPL expression is associated with leukemia. PMID: 22337712
  50. This study shows for the first time a link between homozygous MPL mutations and familial aplastic anemia. It also highlights the important role of MPL in trilineage hematopoiesis. PMID: 22180433
  51. Ligand-inducible dimerization of intracellular Mpl in human myeloerythroid progenitors induces progenitor expansion and erythropoiesis. PMID: 22290824
  52. Selection against TpoR antiproliferative signaling occurs by TpoR down-modulation and that restoration of down-modulated TpoR levels could become a biomarker for the treatment of myeloproliferative neoplasms. PMID: 22378845
  53. The expression of EPOR and TPOR on CD34+ CD59+ bone marrow cells are significantly higher than those on CD34+ CD59- cells of paroxysmal nocturnal hemoglobinuria patients. PMID: 22338178
  54. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. PMID: 21841770
  55. STAT5 phosphorylation levels of EPO and TPO receptors are elevated in bone marrow cells of patients with paroxysmal nocturnal hemoglobinuria. PMID: 22093990
  56. Results suggest that MPL mutations within the TM region could result in conformational changes including tilt and rotation (azimuthal) angles along the membrane axis. PMID: 21858098
  57. Studies indicate that in most of the cases the CAMT is caused by homozygous or compound heterozygous mutations in the gene MPL. PMID: 22102270
  58. MPL mutation is not associated with primary myelofibrosis. PMID: 21691276
  59. Subtle differences in cytokine receptor dimerization provide a new layer of signalling regulation that is relevant for disease. PMID: 21892137
  60. BCR/ABL negative and JAK2V617F-negative myeloproliferative neoplasms patients have other mutations besides W515 mutation in MPL exon10 and mutations other than single nucleotide exchange also exist PMID: 21555228
  61. double mutations in cis of MPL exon 10 in myeloproliferative neoplasms PMID: 21228032
  62. identification and characterization of a founder mutation in MPL in the Ashkenazi Jewish (AJ) population. PMID: 21489838
  63. Data indicate that the precise mechanisms for the different biological effects regarding stimulation through the same receptor, Mpl, remain to be elucidated. PMID: 21605620
  64. Data suggest that signaling and inactive states of thrombopoietin receptor are related by receptor subunit rotations, rather than a simple monomer-dimer transition. PMID: 21402716
  65. MPL exon 10 mutations are associated with myeloproliferative neoplasms. PMID: 21570117
  66. Of 168 pts, 149 with polycythemia vera (PV) and 19 with post-PV myelofibrosis (PV-MF), two pts (1.2%; 1 PV, 1 PV-MF) harbored MPL mutations. Data suggest PV is molecularly more complex than previously appreciated. (study from Mayo Clinic, MN, USA) PMID: 21674576
  67. A recurrent MPL-S505N mutation found in Italian families with hereditary thrombocythemia is likely caused by a founder effect. PMID: 19608689
  68. Patients with familial thrombocytosis caused by MPL serine505asparagine mutation have a high risk of thrombosis, and with aging, develop splenomegaly and bone marrow fibrosis, affecting life expectancy. PMID: 19713221
  69. A point mutation was detected in patients with essential thrombocythemia but not polycythemia vera, idiopathic myelofibrosis, or chronic myelogenous leukemia. PMID: 19099657
  70. mutations in exons 12 to 14 of Jak2 can be used to diagnose myeloproliferative disorders PMID: 21326037
  71. A founder mutation in the MPL gene c.79+2T>A causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population. PMID: 21489838
  72. Mutations in the thrombopoietin receptor gene, c-mpl is associated with congenital amegakaryocytic thrombocytopenia PMID: 21225925
  73. The MPL W515L/K mutations are rare in Taiwanese patients with Ph-negative myeloproliferative neoplasms. PMID: 21051030
  74. The frequencies of the MPL W515L/K mutations with essential thrombocythemia/post-essential thrombocythemia myelofibrosis were 3.2%. PMID: 20890078
  75. in megakaryoblastic cells, PKC plays the crucial role in the initiation of up-regulation of PMA-induced c-mpl promoter activity PMID: 21174945
  76. The MPL W515L mutation and JAK2 exon 12 mutations can also be found in JAK2 V617F negative myeloproliferative disorders patients. PMID: 20331763
  77. MPLW515L mutation is not associated with myelodysplastic syndrome. PMID: 20485371
  78. separate binding sites on the Mpl receptor for TPO and hNUDC identified PMID: 20529857
  79. lack of spontaneous STAT3 and STAT5 activation and the normal response to TPO is unexpected as MPLW515L leads to constitutive receptor activation and hypersensitivity to TPO in experimental models PMID: 20113333
  80. Acquisition of a MPL mutation is not influenced by the presence of JAK2 46/1 haplotype frequency in myeloproliferative neoplasms. PMID: 20111067
  81. MPL W515L/K mutations are associated with chronic myeloproliferative disorders. PMID: 19274616
  82. Propose a gene therapeutic strategy, with c-mpl as the major genetic component, to address the morbidity and mortality resulting from cytopenias in HIV infected patients. PMID: 20232601
  83. No MPL W515L/K expression was found in early myeloproliferative disorders. PMID: 19175989
  84. W515-P518delinsKT are missense mutations in essential thrombocythemia PMID: 19728022
  85. MPL gene mutations seem to be associated with thrombocytosis. PMID: 19643476
  86. Protein kinase C plays the essential role in the modulation of c-mpl promoter activity of megakaryoblastic cells. PMID: 20166549
  87. Results suggest that TpoR cytosolic phosphorylated Y112 and flanking sequences could become targets for pharmacologic inhibition in MPNs. PMID: 19996410
  88. Mpl plays an important and specific role in mediating hNUDC-induced megakaryocyte proliferation and differentiation. PMID: 19560457
  89. binding to platelet thrombopoietin receptor is directly involved in human thrombopoietin plasma level regulation PMID: 11961237
  90. expressed in megakaryocytes in essential thrombocythemia PMID: 12010817
  91. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. PMID: 12091373
  92. A new mutation of MPL, Trp(508) to Ser(508) in the intracellular domain of MPL, induces factor-independent growth in Ba/F3 cells & constitutively activates 3 distinct signaling pathways, SHC-Ras-Raf-MAPK/JNK, JAK-STAT, and PI3K-Akt-Bad. PMID: 12145691
  93. The cytoplasmic domain of Mpl receptor transduces exclusive signals in embryonic and fetal hematopoietic cells. PMID: 12200367
  94. Asn505 is an activating mutation with respect to the intracellular signaling and survival of cells in familial essential thrombocythemia deriving from a dominant-positive activating mutation of the c-MPL gene. PMID: 14764528
  95. the promoter activity of myeloproliferative leukemia virus oncogene is modulated by transcription through a PKC-dependent pathway PMID: 14995067
  96. c-Mpl truncated isoform with an essential C-terminal peptide is required for a proteolytic process PMID: 15210714
  97. K39N represents an identified functional Mpl polymorphism and is associated with altered protein expression of Mpl and a clinical phenotype of thrombocytosis. PMID: 15269348
  98. may play a role in hematopoietic inhibition during HIV-1 infection, and control of its expression levels may aid in hematopoietic recovery and thereby reduce the incidence of cytopenias occurring in infected individuals PMID: 15452260
  99. expression of TPO receptor on platelets until 1 month after birth cause a decreased TPO clearance and keep a high level of free TPO in blood, resulting in the subsequent thrombocytosis in preterm infants. PMID: 15647951
  100. a C-terminal AML1 mutation leads to a decrease in Mpl receptor expression in familial thrombocytopenia PMID: 15741216

Show More

Hide All

Involvement in disease Congenital amegakaryocytic thrombocytopenia (CAMT); Thrombocythemia 2 (THCYT2); Myelofibrosis with myeloid metaplasia (MMM)
Subcellular Location Cell membrane, Single-pass type I membrane protein, Golgi apparatus, Cell surface
Protein Families Type I cytokine receptor family, Type 1 subfamily
Tissue Specificity Expressed at a low level in a large number of cells of hematopoietic origin. Isoform 1 and isoform 2 are always found to be coexpressed.
Database Links

HGNC: 7217

OMIM: 159530

KEGG: hsa:4352

STRING: 9606.ENSP00000361548

UniGene: Hs.82906

Most popular with customers

  Tel: 301-363-4651
  Distributors Worldwide


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1